Nektar Therapeutics(NASDAQ:NKTR) 
Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic...
Website: http://www.nektar.com
Founded: 1990
Full Time Employees: 723
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 8.55
H 9.00
L 7.95
C 8.25
V 4,723,093
10EMA 8.25
20EMA 8.25
60EMA 8.25
120EMA 8.25
250EMA 8.25